86732-22-1

Basic information

• Product Name: 3-Benzyl-3,7-diazabicyclo[3.3.0]octane
• Synonyms: 2-Benzyl-Octahydro-Pyrrolo[3,4-C]Pyrrole HCl;3-Benzyl-3,7-diazabicyclo[3.3.0]octane;3-BENZYL-3,7-DIAZABICYCLO[3.3.0]OCTANE,98%;Octahydro-2-benzylpyrrolo[3,4-c]pyrrole;Pyrrolo[3,4-c]pyrrole, octahydro-2-(phenylmethyl)-;2-BENZYL-OCTAHYDRO-PYRROLO [3,4-C] PYRROLE
• CAS NO: 86732-22-1
• Molecular Formula: C₁₃H₁₈N₂
• Molecular Weight: 202.3
• Product Categories: Amines and Anilines;Heterocycles series
• Mol File: 86732-22-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 416.321°C at 760 mmHg
• Flash Point: 205.584°C
• Appearance: /
• Density: 1.27g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-Benzyl-3,7-diazabicyclo[3.3.0]octane(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzyl-3,7-diazabicyclo[3.3.0]octane(86732-22-1)
• EPA Substance Registry System: 3-Benzyl-3,7-diazabicyclo[3.3.0]octane(86732-22-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 86732-22-1(Hazardous Substances Data)

Usage

General Description

3-Benzyl-3,7-diazabicyclo[3.3.0]octane, also known as BDABO, is a chemical compound that belongs to the family of bicyclic organic compounds. It contains a central diazabicyclo[3.3.0]octane skeleton, with a benzyl group attached to the 3-position. 3-Benzyl-3,7-diazabicyclo[3.3.0]octane is commonly used as a chiral ligand in asymmetric synthesis and catalysis, particularly in the field of organic chemistry. It is known for its ability to facilitate various asymmetric reactions, including asymmetric reduction, oxidation, and carbon-carbon bond formation. BDABO has also been utilized in the pharmaceutical industry for the synthesis of chiral drugs and bioactive compounds. Its unique structure and reactivity make it a valuable tool for the preparation of enantiomerically pure compounds.

InChI:InChI=1/C13H14N2O2/c16-12-10-7-15(8-11(10)13(17)14-12)6-9-4-2-1-3-5-9/h1-5,10-11H,6-8H2,(H,14,16,17)

Upstream product

• 186202-73-3 tert-butyl 5-benzylhexahydropyrrolo[3.4-c]pyrrole-2(1H)-carboxylate 
• 141449-85-6 tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 100-52-7 benzaldehyde 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 848591-86-6 5-benzyltetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione 
• 86731-94-4 1-benzyl-4-benzylcarbamoyl-1H-pyrrole-3-carboxylic acid 
• 86732-04-9 1,N-dibenzyl-1H-pyrrole-3,4-dicarboximide 
• 86731-92-2 1-benzyl-1H-pyrrole-3,4-dicarboxylic anhydride 
• 86731-90-0 1-benzyl-pyrrole-3,4-dicarboxylic acid 
• 86732-32-3 N-benzyltetrahydro-1H-pyrrole-3,4-dicarboximide 

Downstream Products

• 86732-37-8 octahydro-2-benzyl-5-(2-thiazolyl)pyrrolo<3,4-c>pyrrole 
• 1438080-43-3 tert-butyl 5-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438072-41-3 N-(3-chloro-4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438072-47-9 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)quinazolin-4-amine 
• 1438085-57-4 tert-butyl 5-(3-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-22-6 N-(4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438074-40-8 N-(3-ethynyl-4-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438085-62-1 tert-butyl 5-(3-((4-((3-ethynyl-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438085-67-6 tert-butyl 5-(3-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-57-7 N-(3-ethynylphenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1438085-72-3 tert-butyl 5-(3-((4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 
• 1438074-75-9 N-(4-bromo-2-fluorophenyl)-6-(3-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)propoxy)-7-methoxyquinazolin-4-amine 
• 1014702-99-8 C₃₄H₄₅N₅O₃ 
• 1014703-40-2 C₃₃H₄₆FN₅O₃ 

Relevant articles and documents

Identification of benzothiazones containing a hexahydropyrrolo[3,4-: C] pyrrol moiety as antitubercular agents against MDR-MTB

IMB1603, a spiro-benzothiazone compound discovered by our lab, displayed potent anti-MTB activity in vitro and in vivo. In this study, we reported a series of new BTZs containing the hexahydropyrrolo[3,4-c]pyrrol moiety based on the structure of IMB1603. Among them, BTZs 11 and 24 displayed potent anti-MTB (MIC -1), and low cytotoxicity (CC50 > 200 μM), suggesting BTZs 11 and 24 may serve as promising candidates for further study. The molecular docking study of 11 toward DprE was also investigated, and revealed that 11 mimicked the binding pattern of PBTZ169 in the active site of DprE1.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.

NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES

The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).